Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 19/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | PIR | O00625 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.40 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.40 |
| ▸ | STK16 | O75716 | 1/20 | 0.40 |
| ▸ | OXSR1 | O95747 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | FES | P07332 | 1/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
| ▸ | YES1 | P07947 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9967970 | 0.91 | BRAF (0.66) | BRAFCYP2C9 | |
| SCHEMBL9967969 | 0.80 | BRAF (0.85) | BRAF | |
| SCHEMBL9932533 | 0.80 | LMNA (0.38) | BRAFLMNAAURKAFGFR1KDR | |
| SCHEMBL9932530 | 0.78 | LMNA (0.37) | BRAFLMNAAURKAFGFR1KDR | |
| SCHEMBL9967975 | 0.78 | BRAF (0.58) | BRAFRAF1CYP2C9BMPR1BPLK4 | |
| SCHEMBL11971630 | 0.77 | BRAF (0.68) | BRAFRAF1CYP2C9BMPR1BPLK4 | |
| SCHEMBL8289376 | 0.76 | BRAF (0.82) | BRAFRAF1CYP2C9BMPR1BPLK4 | |
| SCHEMBL9967973 | 0.74 | BRAF (0.63) | BRAFLMNARAF1CYP2C9 | |
| SCHEMBL9967960 | 0.73 | BRAF (0.75) | BRAFRAF1CYP2C9 | |
| SCHEMBL9967962 | 0.71 | BRAF (0.77) | BRAFRAF1CYP2C9BMPR1BPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025947-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157453-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | BRAF 1/4885LMNA 1519/4885RAF1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.